All Photos(1)

Documents

COO/COA

Y0000009

Fluphenazine enantate

Name: Fluphenazine enantate
Brand: SIAL

European Pharmacopoeia (EP) Reference Standard

Sign Into View Organizational & Contract Pricing

All Photos(1)

Synonym(s):

2-[4-[3-[2-(Trifluoromethyl)phenothiazin-10-yl]propyl]-1-piperazinyl]ethyl heptanoate

Empirical Formula (Hill Notation):

C₂₉H₃₈F₃N₃O₂S

CAS Number:

2746-81-8

Molecular Weight:

549.69

UNSPSC Code:

41116107

NACRES:

NA.24

grade

pharmaceutical primary standard

API family

fluphenazine

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

InChI

1S/C29H38F3N3O2S/c1-2-3-4-5-11-28(36)37-21-20-34-18-16-33(17-19-34)14-8-15-35-24-9-6-7-10-26(24)38-27-13-12-23(22-25(27)35)29(30,31)32/h6-7,9-10,12-13,22H,2-5,8,11,14-21H2,1H3

InChI key

LRWSFOSWNAQHHW-UHFFFAOYSA-N

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Fluphenazine enantate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Product No.

Description

Pricing

1282026

Pictograms

GHS06,GHS08

Signal Word

Danger

Hazard Statements

H301,H360

Precautionary Statements

P201 - P301 + P310 + P330

Hazard Classifications

Acute Tox. 3 Oral - Repr. 1A

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Induction of tardive dyskinesia in Cebus apella and Macaca speciosa monkeys: a review.

E F Domino

Psychopharmacology. Supplementum, 2, 217-223 (1985-01-01)

Two different studies were performed in subhuman primates in an attempt to induce symptoms of tardive dyskinesia. The first study lasted for over 5 years. This involved elderly Macaca speciosa. The animals were given first 25 mg of fluphenazine decanoate

A monkey model of tardive dyskinesia (TD): evidence that reversible TD may turn into irreversible TD.

B Kovacic et al.

Journal of clinical psychopharmacology, 2(5), 305-307 (1982-10-01)

Three Cebus apella monkeys were treated with biweekly injections of fluphenazine enanthate for 1 year. Two distinct motor syndromes were produced. The first consisted of acute dystonic, dyskinetic, parkinsonian, and akathisia-like reactions, which worsened after each injection, were not exacerbated

More than mere shots.

R Walton

The American journal of nursing, 88(5), 664-667 (1988-05-01)

Neuroleptic malignant syndrome.

M P Rampertaap

Southern medical journal, 79(3), 331-336 (1986-03-01)

The neuroleptic malignant syndrome (NMS) is a rare but potentially lethal disorder associated with the administration of neuroleptic agents. This syndrome may be underdiagnosed because it is poorly understood and often unrecognized. It affects all age groups and has a

Monkey models of tardive dyskinesia.

E F Domino et al.

Modern problems of pharmacopsychiatry, 21, 21-33 (1983-01-01)

View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service